DRKS00030696RecruitingNot Applicable
ong term follow up after colorectal EFTR using the full thickness resection device (FTRD)
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- niversitätsklinikum Freiburg
- Enrollment
- 141
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •All patients who underwent follow-up colonoscopy after a mean follow-up period of three years (at least 1 year).
Exclusion Criteria
- •Patients who died before the end of the follow-up (FU) period of 1 year due to other causes not related to the procedure, who underwent surgery on the corresponding bowel area for other reasons during the FU period, who did not undergo a further check-up or for whom the procedure was primarily not succesfull.
Investigators
Similar Trials
Not yet recruiting
Not Applicable
EFTR vs. conventional endoscopic therapy for recurrent or incompletely resected non-lifting colorectal adenomasD12.0D12.2CaecumAscending colonDRKS00023539niversitätsklinikum Freiburg222
Completed
Not Applicable
Standardized long-term follow-up after endoscopic resection of large, nonpedunculated colorectal lesions — a prospective two-center studyC18Malignant neoplasm of colonDRKS00004904Dr. Horst-Schmidt-Klinik240
Completed
Not Applicable
Endoscopic surveillance after curative endoscopic submucosal dissection for early gastric cancer and Helicobacter pylori eradication: multicenter retrospective study.Gastric cancerJPRN-UMIN000011826Ishikawa Prefectural Central Hospital1,500
Not yet recruiting
Not Applicable
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
Active, not recruiting
Phase 1
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2022-002440-40-DESangamo Therapeutics France SAS15